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AbstrAct
We investigated the biological role of CD133-expressing liver cancer stem cells 
(CSCs) enriched after irradiation of Huh7 cells in cell invasion and migration. We 
also explored whether a disintegrin and metalloproteinase-17 (ADAM17) influences 
the metastatic potential of CSC-enriched hepatocellular carcinoma (HCC) cells 
after irradiation. A CD133-expressing Huh7 cell subpopulation showed greater 
resistance to sublethal irradiation and specifically enhanced cell invasion and 
migration capabilities. We also demonstrated that the radiation-induced MMP-2 and 
MMP-9 enzyme activities as well as the secretion of vascular endothelial growth 
factor were increased more predominantly in Huh7CD133+ cell subpopulations than 
Huh7CD133− cell subpopulations. Furthermore, we showed that silencing ADAM17 
significantly inhibited the migration and invasiveness of enriched Huh7CD133+ cells 
after irradiation; moreover, Notch signaling was significantly reduced in irradiated 
CD133-expressing liver CSCs following stable knockdown of the ADAM17 gene. In 
conclusion, our findings indicate that CD133-expressing liver CSCs have considerable 
metastatic capabilities after irradiation of HCC cells, and their metastatic capabilities 
might be maintained by ADAM17. Therefore, suppression of ADAM17 shows promise 
for improving the efficiency of current radiotherapies and reducing the metastatic 
potential of liver CSCs during HCC treatment.
IntroductIon
Hepatocellular carcinoma (HCC) is one of the 
most devastating malignancies worldwide and is highly 
prevalent in sub-Saharan Africa and Southeast Asia; 
moreover, its incidence is currently increasing in Western 
countries [1, 2]. Although remarkable advances in the 
treatment of HCC have been made, its prognosis is poor 
due to a high tumor recurrence rate that exceeds 70% after 
surgical resection [3] and progressive liver failure caused 
by underlying liver cirrhosis. Among multiple modalities 
for the treatment of HCC, radiotherapy has been applied 
in selected cases. Because liver tissue is highly sensitive 
to radiation, high-dose conventional radiotherapy against 
HCC is generally limited due to radiation-induced liver 
injury. To compensate for this drawback, stereotactic 
body radiation therapy (SBRT) is recommended for 
HCC; however, evidence of beneficial survival outcomes 
for advanced HCC remains insufficient [4]. Recently, 
the hazards of radiotherapy have been shown in cancer 
biology and clinically based studies, such as enhancement 
of cancer cell invasiveness in vitro [5] and an increase in 
distant metastasis in some cancer patients [6, 7]. However, 
the mechanisms underlying metastasis in HCC after 
irradiation have not been clarified. 
Growing evidence reveals that a subpopulation of 
tumor cells harboring the ability to propagate, called cancer 
stem cells (CSCs) or cancer stem-like cells (CSLCs), 
is responsible for tumor initiation, progression and 
metastasis. In addition, recent studies have described that 
CSCs in a variety of human tumors play a key role in tumor 
recurrence, chemoresistance and radioresistance [8–11]. 
However, knowledge regarding the role of candidate 
CSCs in radioresistance of HCC is limited. Regarding 
radioresistance associated with CSCs, a previous study 
reported that glioma stem cells promote radioresistance 
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via preferential activation of the DNA damage response 
[12], and another study demonstrated that radioresistance 
is associated with reactive oxygen species (ROS) levels 
in CSCs [13]. We recently demonstrated that CD133-
expressing liver cancer cells following radiation exposure 
showed higher activation of the MAPK/PI3K signaling 
pathway and reduced ROS levels compared with CD133 
(−) liver cancer cells [14]. However, the mechanism by 
which irradiation maintains or reinforces the invasion 
and migration capabilities of CSCs, which reflects 
the metastatic potential of tumor cells, remains to be 
explored. A previous study demonstrated that radiation 
enhanced HCC cell invasiveness by MMP-9 expression 
through the PI3K/Akt/NF-kappaB signal transduction 
pathway [15]. Additionally, another study showed that 
radiation enhances the long-term metastatic potential of 
residual HCC through the TMPRSS4-induced epithelial-
mesenchymal transition in nude mice [16]. However, 
whether activation of a particular gene related to liver 
CSCs can lead to metastasis in HCC remains unclear. 
A disintegrin and metalloproteinase (ADAM), also 
known as TNF-α converting enzyme (TACE), plays a 
key developmental role by processing numerous growth 
factors and growth factor receptors [17, 18]. Studies have 
shown that ADAM17 is a potent sheddase of the epidermal 
growth factor (EGF) family of ligands and regulates EGFR 
activity in a variety of tumors [19, 20]. Additionally, 
ADAM17 plays important roles in tumor progression 
[21], hypoxia-induced tumor cell invasiveness [22] and 
hypoxia-induced cisplatin resistance [23]. In the present 
study, we found that ADAM17 was increased in irradiated 
liver CSCs, suggesting their involvement in the metastatic 
mechanism of HCC, and furthermore, this metastatic 
potential of liver CSCs may be decreased by ADAM17. 
Moreover, aberrant Notch signaling was reportedly related 
to tumorigenesis, self-renewal of CSCs and metastasis in 
various human tumors [24], and its downregulation was 
found to inhibit HCC cell invasion through inactivation 
of matrix metalloproteinase 2 (MMP-2), MMP-9 and 
vascular endothelial growth factor (VEGF) [25]. However, 
how ADAM17 regulates Notch signaling in liver CSCs 
after irradiation remains unclear.
In the present study, we explored whether ADAM17 
in CD133-expressing liver CSCs plays a key role in 
radiation-induced tumor cell invasiveness or the metastatic 
potential of HCC.
results
the cd133-expressing Huh7 cell subpopulation 
exhibited metastatic potential with 
radioresistance properties
Recent studies reported that irradiation enriches 
the population of cells expressing CSC markers [26]. 
In our previous study, we found that CD133 expression 
was significantly higher in 15- Gy irradiated Huh7CD133+ 
cells than in nonirradiated Huh7CD133+ cells. In addition, 
Huh7CD133+ cells may have greater anti-apoptotic activity 
due to increased Bcl-2 expression and radioresistance. 
These CSCs are radioresistant to both intrinsic and extrinsic 
determinants through various mechanisms, including 
preferential activation of the DNA damage response, lower 
cellular ROS levels and activation of survival signaling 
pathways [12]. Furthermore, in a growing tumor, CSCs 
regulate metastasis similar to normal stem cell processes 
[27]. The typical human HCC cell lines include Huh7, 
Hep3B, HepG2, Sk-hep1, PLC/PRF5 cell, among others. 
In this study, we isolated liver cancer stem cells (LCSCs) 
from various HCC cell lines using a PE-conjugated anti-
CD133 antibody and a FACs system. In Supplementary 
Figure S1, we confirmed CD133-expressing LCSCs 
population in various HCC cell lines by FACs. The 
percentage of CD133 (+) LCSCs from the Sk-Hep1 cell 
line was only 0.1%, and therefore we could not use this 
cell line for further study. By contrast, the percentages of 
CD133 (+) LCSCs from Hep3B and PLC/PRF5 cell lines 
were 98.9% and 86.2%, respectively, and these cells also 
were inappropriate for further study. However, the ratios 
of CD133 (+) cells and CD133 (−) cells from the Huh7 
cell line were 50.7% and 49.3%, respectively, which 
rendered it appropriate for use in further experiments. 
To determine whether Huh7CD133+ cells possessed greater 
metastatic ability than their Huh7CD133− cell counterparts 
in vitro, we performed a migration assay of Huh7CD133+ 
and Huh7CD133− cells sorted from the Huh7 cell line. At 12, 
24 and 48 h after 15- Gy irradiation, the migrated cells in 
each well were stained using a Diff-Quik three-step stain 
kit (Figure 1A). Then, the numbers of migrated Huh7CD133+ 
cells and Huh7CD133− cells were counted and compared 
(Figure 1B). As shown in Figure 1B, the migration 
ability of Huh7CD133+ cells was twofold higher than that 
of Huh7CD133− cells at 48 h after 15- Gy irradiation. Next, 
to assess the invasion ability of Huh7CD133+ and Huh7CD133− 
cells after 15- Gy irradiation, we measured and compared 
the optical density (OD) values obtained an invasion assay 
(Figure 1C). At 48 h after 15- Gy irradiation, the invasion 
ability of Huh7CD133+ cells was significantly higher than that 
of Huh7CD133− cells. Taken together, these results suggest 
that irradiation exerts significantly greater stimulatory 
effects on the migration and invasion of Huh7CD133+cells 
than Huh7CD133−cells. Moreover, these results provided 
additional evidence that compared with Huh7CD133−cells, 
Huh7CD133+cell subpopulations are enriched in CSCs 
resistant to irradiation.
secretion of MMP-2 and MMP-9 by the cd133-
expressing Huh7 cell subpopulation following 
irradiation
MMP enzymes that degrade ECM proteins are a 
critical component of cell invasion in metastasis [15]. 
Oncotarget23484www.impactjournals.com/oncotarget
In this study, we investigated the gelatinolytic activities 
of MMP-2 and MMP-9 after 15- Gy irradiation. The 
radiation-induced MMP-2 and MMP-9 enzyme activities 
determined by gelatin zymography were significantly 
increased in Huh7CD133+ cell supernatants (Figure 2A–2C). 
As shown in Figure 2B, MMP-2 activity at 12, 24 and 
48 h after 15- Gy irradiation was significantly increased 
in Huh7CD133+ cell supernatants compared with Huh7CD133− 
cell supernatants. Additionally, MMP-9 activity at 24 and 
48 h after 15- Gy irradiation was significantly increased 
in Huh7CD133+ cell supernatants compared with the control 
(Figure 2C). These results suggest that upregulation of 
MMP-2 and MMP-9 secretion after irradiation enhances 
the invasiveness of liver CSCs.
secretion of VeGF in cd133-expressing Huh7 
cell subpopulations following irradiation
The expression of VEGF, an important growth factor 
stimulating angiogenesis, has been associated with tumor 
Figure 1: Migration and invasion assay of Huh7cd133+ and Huh7CD133− cells after 15- Gy irradiation. (A) The migratory 
capacity of Huh7CD133+ and Huh7CD133− cells was assessed at 12, 24 and 48 h using a Transwell migration assay after 15- Gy irradiation. 
(b) The numbers of migrated Huh7CD133+ and Huh7CD133- cells was compared. The results are expressed as means ± SD of three independent 
experiments. **P < 0.01, Huh7CD133+ (48 h) vs. Huh7CD133− (48 h). (c) Invasive potential of Huh7CD133+ and Huh7CD133− cells was measured 
using Matrigel-coated transwells after 48 h of 15- Gy irradiation. The results are expressed as means ± SD of three independent experiments. 
*P < 0.05, Huh7CD133+ vs. Huh7CD133− cells. 
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progression, metastasis and invasion in HCC [28] and 
other tumors [29]. A previous study reported that VEGF 
levels were enhanced by ionizing radiation in glioblastoma 
cells [30]. In this regard, we investigated whether the 
metastatic potential of liver CSCs after 15- Gy irradiation 
is associated with VEGF expression levels by Western 
blot and enzyme-linked immunosorbent assay (ELISA). 
As shown in Figure 2D, the rate of increase in VEGF 
expressions in irradiated Huh7CD133+ cells increased over 
time compared with irradiated Huh7CD133− cells determined 
by Western blot. In addition, the increased VEGF levels 
in supernatants from irradiated Huh7CD133+ cells tended to 
increase over time compared with irradiated Huh7CD133− 
cells albeit not significantly so (Figure 2E). These 
corresponding results from Western blots and ELISA 
indicate that CD133-expressing LCSCs after radiation 
have greater angiogenic potential, leading to enhanced 
metastatic ability.
cd133 expression following irradiation 
increased metastatic potential in vivo
To determine the effect of CD133-expressing 
LCSCs following radiation treatment on metastatic 
potential in vivo [31], irradiated Huh7CD133+ or Huh7CD133− 
were injected via the tail vein. At 10 weeks after tumor cell 
injection via the tail vein, lung metastases were detected 
in 7 (70%) of the 10 mice injected with 1 × 106 Huh7CD133+ 
cells after irradiation but not in the 10 mice injected with 
Huh7CD133− cells (Table 1, Figure 3A). In the representative 
H & E staining of the lung tissues in Huh7CD133+ injection 
group, tumors exhibited more aggressive invasion into 
surrounding lung tissue, undifferentiated and markedly 
pleomorphic tumor cells, suggesting poorly differentiated 
carcinoma (Figure 3B). In addition, subcutaneous 
metastases were detected in 2 of 10 mice with 1 × 106 
Huh7CD133+ cells. However, no metastases were observed 
in the heart, kidney, spleen or liver in this group. These 
findings suggest that CD133-expressing LCSCs after 
irradiation have metastatic potential.
Differential profiling of metastasis-associated 
gene expression between Huh7cd133+ and 
Huh7CD133− cells following irradiation
To evaluate how the cellular processes of Huh7CD133+ 
and Huh7CD133+ cells differ after irradiation, a cDNA 
microarray was used to analyze the gene expression profiles 
Figure 2: Gelatin zymography using conditioned Huh7cd133+ and Huh7CD133− cell culture media after 15- Gy irradiation. 
(A) MMP activities are visualized as white (clear) bands, corresponding to MMP-2 and MMP-9. (b and c) MMP-2 and MMP-9 band 
densities were quantified. The results are expressed as means ± SD of three independent experiments. **P < 0.01 vs. Huh7CD133+ and 
Huh7CD133− controls. *P < 0.05 vs. Huh7CD133+ and Huh7CD133− controls. (d) VEGF expression levels in Huh7CD133+ and Huh7CD133− cells after 
15- Gy irradiation were compared by Western blotting. (e) VEGF protein levels in conditioned media from Huh7CD133+ and Huh7CD133− cells 
after 15- Gy irradiation were compared by ELISA. 
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Figure 3: Gross photography of dissected organs and H & e staining from representative tumor from metastasis 
in vivo model. (A) Representative images of dissected organs within the body after tail vein injection of irradiated Huh7CD133+ and 
Huh7CD133− cells. Multiple nodules were observed in both lung but none in Huh7CD133− injection group. In addition, no metastatic lesions were 
found in other organs except lung. (b) Representative H & E staining of the lung tissues in Huh7CD133+ injection group showed tumorous 
portion (T) and non-tumorous portion (NT). Tumors exhibited more aggressive invasion into surrounding lung tissue, undifferentiated and 
markedly pleomorphic tumor cells, suggesting poorly differentiated carcinoma. Scale bar, 200 μm.








Hematogenic metastases subcutaneous 
tumor 
formationlung liver spleen Kidney Heart
Huh7CD133+ i.v. 106 10 10 7/10 0/10 0/10 0/10 0/10 2/10
Huh7CD133− i.v. 106 10 10 0/10 0/10 0/10 0/10 0/10 0/10
*i.v.: Intravenous injection.
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of Huh7CD133+ and Huh7CD133− cells at 12 and 24 h after 
15- Gy irradiation. The mRNA expression profiles of 
Huh7CD133+ and Huh7CD133− cells were comparatively 
analyzed using a cDNA microarray containing 592 genes. 
Fifteen percent of the genes (89 genes) that displayed 
a greater than 1.5-fold change in Huh7CD133+ expression 
compared with the control Huh7CD133− cells were associated 
with metastasis (Figure 4A). Grouping of the 89 metastasis-
associated genes according to their biological function was 
performed between Huh7CD133+ and Huh7CD133− cells at 12 
and 24 h after irradiation. Among the genes increased in 
Huh7CD133+ cells 12 h post-irradiation, 13.5% (12 genes) 
were related to migration, 29.2% (26 genes) to cell 
adhesion, 25.8% (23 genes) to cell mobility and 7.8% to 
angiogenesis. Additionally, of the genes that were increased 
24 h post-irradiation, 12.3% (11 genes) were associated 
with migration, 38.2% (34 genes) with cell adhesion, 32.6% 
(29 genes) with cell mobility, 9% (9 genes) with 
angiogenesis and 6.7% (6 genes) with VEGF signaling. 
Among the genes, for validation we selected 14 candidate 
reference genes (ADAM17, ADCY3, ALDH2, ALDH3, 
ALDH7, BOLA2, LEPR, MTSS1, NME1, KRT18, 
Notch1, PHLDA1, PDGFR and FANCD2) that showed 
overlapping upregulation at 12 and 24 h post-irradiation in 
Huh7CD133+ cells. Reverse transcription polymerase chain 
reaction (RT-PCR) for validation of selected candidate 
genes was performed in sorted Huh7CD133+ and Huh7CD133− 
cells (Supplementary Table S1). However, only two 
genes showed at least a 1.5-fold difference: ADAM17 
was increased 1.9-fold and metastasis suppressor 1 
(MTSS1) was decreased 0.5-fold in Huh7CD133+ cells 
compared with Huh7CD133− cells (Figure 4B). ADAM17 
is a transmembrane and secreted protein with important 
roles in various metastatic functions, such as adhesion, 
migration, invasion and secretion of MMP-2 and 
MMP-9 [32]. In contrast, MTSS1 reportedly exerts its 
metastasis suppressor functions by acting as a scaffold 
protein that interacts with actin-associated proteins 
to regulate lamellipodia formation [33]. Therefore, 
we assessed the effect of ADAM17 on metastasis potential 
in CD133-expressing LCSCs after irradiation.
expression of AdAM17 in cd133-expressing 
liver cscs following irradiation 
To confirm the difference in ADAM17 protein 
levels in Huh7CD133+ and Huh7CD133− cells after irradiation, 
cells were cultured and harvested at 12, 24 and 48 h after 
15- Gy irradiation. Western blot was performed using 
antibodies against ADAM17. The ADAM17 protein level 
was increased significantly in Huh7CD133+ cells compared 
with the control at 12, 24 and 48 h after treatment with 
15- Gy irradiation. However, the ADAM17 protein level 
was significantly decreased in Huh7CD133− cells compared 
with the control (Figure 4C and 4D). Additionally, the 
MTSS1 protein level was not changed in Huh7CD133+ or 
Huh7CD133− cells at 12, 24 and 48 h after irradiation, in 
agreement with the mRNA level based on RT-PCR, but 
no significant difference between the two cell groups 
was observed (Supplementary Figure S2A and S2B). 
These results suggest that overexpression of ADAM17 
is associated with cell invasiveness, angiogenesis and 
migration, and could contribute to metastasis after 
radiotherapy for the treatment of HCC.
AdAM17 mediates cell migration, invasion and 
wound healing in cd133-expressing liver cscs 
following radiation exposure
ADAM17 promotes tumor-induced angiogenesis 
through upregulation of growth factors such as VEGF 
via MAP kinase activation [34]. In the present study, 
ADAM17 in Huh7CD133+ cells (high metastatic potential) 
was knocked down using small interfering RNA (siRNA) 
to suppress metastasis. To assess whether the migration 
activity of CD133-expressing liver CSCs is influenced by 
ADAM17 silencing, Huh7CD133+ and Huh7CD133− cells were 
transfected with 10 nM siADAM17 or 10 nM scrambled 
siRNA. ADAM17 expression after ADAM17 siRNA 
(10 nM) transfection was markedly suppressed (greater 
than 80%) in both cell types within 2 days, whereas no 
change in ADAM17 expression was observed in either cell 
type following treatment with scrambled siRNA (10 nM) 
(Figure 5A). Next, we investigated whether silencing of 
ADAM17 expression decreased the migration ability of 
liver CSCs after irradiation. In both cell types treated with 
mock siRNA, the migration ability of Huh7CD133+ cells was 
higher than that of Huh7CD133− cells (Figure 5B), indicating 
the metastatic potential of CD133-expressing liver CSCs. 
Notably, we found that the migration ability of Huh7CD133+ 
cells was significantly reduced after silencing ADAM17 
compared with mock control and scrambled siRNA, 
while that of Huh7CD133− cells was unchanged (Figure 5B). 
These results suggest that ADAM17 expression in 
CD133-expressing liver CSCs plays a pivotal role in the 
metastasis of HCC after irradiation. To suppress ADAM17 
expression effectively, stable cell lines expressing shRNA 
against human ADAM17 were generated by lentiviral 
transductions in Huh7 cells. As shown in Figure 5C and 5D, 
ADAM17 mRNA and protein levels were suppressed 
effectively in ADAM17 transfected Huh7 cells compared 
with cells expressing negative control shRNA (shNC). 
Furthermore, shADAM17CD133+ and shADAM17CD133− 
cells following sorting using an anti-CD133 FACs 
antibody were suppressed compared with their shNC 
controls (Supplementary Figure S3A). In addition, 
CD133 protein levels were decreased in shADAM17CD133− 
and shNCCD133− cells after sorting (Supplementary 
Figure S3B). After successful establishment of the stable 
ADAM17 knockdown cell line, we investigated whether 
knockdown of ADAM17 suppresses the metastatic 
potential of CD133-expressing liver CSCs, such as their 
wound healing, migration and invasion, after 15- Gy 
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irradiation. Four cell groups (Huh7CD133+, Huh7CD133−, 
shNCCD133+ and shADAM17CD133+) were examined in 
terms of their wound healing abilities analyzed after 
15- Gy irradiation. The wound healing ability of 
shADAM17CD133+ cells was significantly inhibited at 
48 h compared with shNCCD133+ cells and Huh7CD133+ 
cells. However, no changes in the wound healing ability 
of Huh7CD133− cells were observed compared with 
the control (Figure 6A and 6B). Next, we performed 
migration assays. As shown in Figure 6C and 6D, 
silencing of ADAM17 by shRNA in Huh7CD133+ cells 
significantly inhibited migration ability at 48 h compared 
with that of shNCCD133+ cells and Huh7CD133+ cells. In 
addition, we performed invasion assays to determine the 
invasiveness of liver CSCs after irradiation. The invasion 
rate of shADAM17CD133+ was significantly lower than that 
of shNCCD133+ cells (Figure 6E). Moreover, we assayed 
VEGF levels in shADAM17CD133+ and shNCCD133+ cell 
culture media over time after irradiation. The VEGF levels 
in shADAM17CD133+ cell culture medium were significantly 
decreased at 24 and 48 h after irradiation compared with 
shNCCD133+ cell culture medium (Supplementary Figure S4). 
Taken together, these results demonstrated that silencing 
of ADAM17 significantly inhibited the migration and 
invasiveness of liver CSCs after irradiation, suggesting 
that suppression of ADAM17 after radiotherapy could 
prevent metastasis in HCC.
suppression of AdAM17 inhibits the migration 
ability of liver cscs in vivo
Although in vitro studies elucidated the role of 
ADAM17 in the metastatic mechanism of CD133-
expressing liver CSCs after irradiation, further in vivo 
evidence is necessary to confirm the role of ADAM17. 
First, we confirmed that the migration ability of irradiated 
Figure 4: cDNA microarray analysis of the expression profiles of metastasis-associated genes in Huh7cd133+ and 
Huh7CD133− cells at 12 and 24 h after 15- Gy irradiation. (A) DEGs between Huh7CD133+ and Huh7CD133− cells. The columns show 
DEGs in Huh7CD133+ and Huh7CD133− cells at 12 and 24 h. Colors represent increases (red) and decreases (green) in CD133+ expression under 
each condition. (b) The expression levels of metastasis-associated genes were validated in Huh7CD133+ and Huh7CD133− cells at 12 and 24 h 
after 15- Gy irradiation using RT-PCR. (c) Western blot analysis of ADAM17 protein levels after 15- Gy irradiation of Huh7CD133+ 
and Huh7CD133− cells. β-actin was used as a loading control. (d) Band densities were quantified using the TINA imaging analysis software 
and normalized to β-actin expression. The data shown are the means ± SE of three independent experiments. **P < 0.01 vs. Huh7CD133+ and 
Huh7CD133+ controls. *P < 0.05 vs. Huh7CD133− and Huh7CD133− controls.
Oncotarget23489www.impactjournals.com/oncotarget
Huh7CD133+ and Huh7CD133− cells after intrasplenic vein 
delivery could be visualized by in vivo NIR fluorescence 
imaging (Supplementary Figure S5A). Cells were labeled 
with NIR 797 24 h before intrasplenic vein injection. 
Cells (2 × 105) from each group were injected and the 
NIR signal intensity monitored. Ten days after injection, 
Huh7CD133+ and Huh7CD133 cells migrated out of the spleen 
toward other organs (liver and lung), and the cell migration 
area percentages were analyzed using the maestro imaging 
system (Supplementary Figure S5B). The migration area 
percentage of Huh7CD133+ cells increased to a greater degree 
than that of Huh7CD133− cells after irradiation. Furthermore, 
the NIR fluorescent signal intensity of shNCCD133+ cells in 
the abdomen increased over time and spread throughout 
the body of nude mice, whereas the fluorescent signal 
intensity of shADAM17CD133+ cells slowly increased in the 
abdomen and their spread throughout the body was delayed 
(Figure 7A and 7B). These results demonstrated that the 
overall NIR fluorescent signal intensity was significantly 
reduced in the mice injected with ADAM17-suppressed 
Huh7CD133+ cells compared with ADAM17-nonsuppressed 
Huh7CD133+ cells. After imaging analysis, the mice were 
sacrificed on day 10 and the liver, kidney, spleen, lung 
and heart were harvested for imaging of the individual 
organs. NIR-stained shNCCD133+ cells migrated to the liver, 
kidney, spleen, lung and heart 10 days after intrasplenic 
vein injection, while NIR-stained shADAM17CD133+ cells 
slowly migrated to other organs after injection (Figure 7C 
and 7D). Furthermore, to identify the human-derived 
migrated cells in the liver of the nude mice after 
Figure 5: establishment of an AdAM17-knockdown cell line using a lentiviral expression system. (A) ADAM17 mRNA 
expression in Huh7CD133+ and Huh7CD133− cells at 24 h determined by RT-PCR following transfection of ADAM17 siRNA. (b) Transwell 
migration assays of Huh7CD133+, Huh7CD133−, scram siRNA Huh7CD133+and ADAM17 siRNA Huh7CD133+ cells after 15- Gy irradiation. Images 
were captured at 48 h under × 40 magnification. The numbers of migrated Huh7CD133+, Huh7CD133−, scram siRNA Huh7CD133+and ADAM17 
siRNA Huh7CD133+ cells were compared. **P < 0.01, Huh7CD133+ (48 h) vs. Huh7CD133− cells (48 h). ***P < 0.001, Huh7CD133+ (48 h) vs. 
siADAM17 Huh7CD133+ cells (48 h) (c) ADAM17 mRNA levels in shNC and shADAM17 cells were analyzed using RT-PCR after infection 
with lentivirus. Band densities were quantified using the TINA imaging analysis software and normalized to β-actin expression. The data 
shown are the means ± SE of three independent experiments. **P < 0.01 vs. shNC cells and shADAM17 cells. (d) ADAM17 protein 
levels in shNC and shADAM17 cells were analyzed by Western blot analysis after infection with lentivirus. Band densities were quantified 
using the TINA imaging analysis software and normalized to β-actin expression. The data shown are the means ± SE of three independent 
experiments. ***P < 0.001 vs. shNC cells and shADAM17 cells.
Oncotarget23490www.impactjournals.com/oncotarget
intrasplenic vein injection, immunohistochemical staining 
for human albumin was performed. The expression levels 
of human albumin were markedly higher in the livers 
of nude mice injected with shNCCD133+ cells compared 
with those injected with shADAM17CD133+ (Figure 7E). 
These results provide evidence that ADAM17 inhibits the 
migration and metastatic potential of CD133-expressing 
liver CSCs after radiotherapy and may serve as a 
prognostic marker of recurrence and metastasis of HCC 
following radiotherapy. 
the notch signaling pathway is inhibited by 
suppression of AdAM17 in cd133-expressing 
liver cscs
The Notch, Hedgehog and Wnt signaling pathways 
are involved in metastasis of liver CSCs to distant organs 
[35]. ADAM17 is an activator of the Notch pathway 
and is overexpressed in a variety of diseases, including 
cancers [36]. Among these pathways, Notch signaling 
reportedly affects angiogenesis [37] and metastasis [38]. 
The Notch intracellular domain (NICD) is cleaved from 
the plasma membrane and translocates into the nucleus 
forming a transcriptional activation complex after binding 
to CSL/RBPJk/Su(H) and Mastermind (MAML). This 
heteromeric complex activates the transcription of target 
genes such as HES [39]. In the present study, to determine 
the association of Notch signaling with liver CSCs with 
high metastatic potential after irradiation, we assessed the 
expression of NICD in the ADAM17-suppressed CD133-
expressing liver CSCs after irradiation using Western 
blotting. NICD expression was reduced significantly in 
shADAM17CD133+ cells at 24 and 48 h after irradiation 
compared with that in shNCCD133+ cells (Figure 8A and 8B). 
Figure 6: changes in shAdAM17cd133+ and shnccd133+ cell migration after 15- Gy irradiation. (A) Wound healing assay 
in Huh7CD133+, Huh7CD133−, shNCCD133+ and shADAM17CD133+ after 15- Gy irradiation. Four group of cells were plated on 24-well plates 
(1 × 105 cells /well) and wounded with a disposable pipette tip. Wound closure was monitored for 48 h after irradiation. (b) Cell wound area 
percentages were analyzed using Optimas 6.5 software and compared with those at time zero. ***P < 0.001, Huh7CD133+ (48 h) vs. Huh7CD133+ 
cells (0 h). **P < 0.01, Huh7CD133− (48 h) vs. Huh7CD133− cells (0 h). **P < 0.01, shNCCD133+ (48 h) vs. shNCCD133+ cells (0 h). **P < 0.01, 
shADAM17CD133+ (48 h) vs. shADAM17CD133+ cells (0 h). (c) Migrated cells stained crystal violet (purple color). (d) Migrated cells 
(purple area) were quantified based on optical density (OD) values. *P < 0.05, Huh7CD133+ (48 h) vs. Huh7CD133− cells (48 h). *P < 0.05, 
shADAM17CD133+ (48 h) vs. Huh7CD133+ cells (48 h). (e) Invasion assay of shADAM17CD133+ and shNCCD133+ cells was using Matrigel-coated 
Transwells. *P < 0.05, shADAM17CD133+ (48 h) vs. shNCCD133+ (48 h).
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Furthermore, to determine whether NICD translocates into 
the nucleus and activates transcription of genes, HES1 
protein levels were determined using Western blotting. 
As shown in Figures 8C and 8D, HES1 expression was 
reduced significantly at 24 and 48 h after irradiation in 
shADAM17CD133+ cells compared with shNCCD133+ cells. 
Taken together, our results suggest that the Notch pathway 
is inhibited by suppression of ADAM17 during metastasis 
of CD133-expressing liver CSCs after radiotherapy. 
dIscussIon
In the present study, we showed that stem-like cells 
play an important role in the radioresistance and metastatic 
potential of HCC. More specifically, the CD133-
expressing Huh7 cell subpopulation showed greater 
resistance to sublethal irradiation and enhanced invasion 
and migration, which reflect metastatic potential. In the 
present study, our results demonstrated that irradiated 
CD133 (+) LCSCs have more predominantly metastatic 
potential than CD133 (−) LCSCs in the metastasis in vivo 
mice model which was established by tail vein injection 
of tumor cells. These results are consistent with a previous 
report that CD133-expressing cancer stem cells within 
gliomas are less sensitive to radiation-induced apoptosis 
and the fraction of CD133-expressing cells is increased 
in in vitro cultures after irradiation [12]. We recently 
revealed that CD133-expressing liver cancer cells have 
anti-apoptotic and radioresistance properties which are 
mediated by activation of the MAPK/PI3K signaling 
pathway [14]. Given the high tumorigenic capacity of 
HCC stem cells, disrupting the radioresistance of liver 
CSCs may enhance the efficacy of radiotherapy for HCC.
MMP activation in tumor metastasis allows tumor 
cells to access blood vessels, migrate to and invade target 
organs, ultimately leading to metastasis [40]. Among them, 
Figure 7: the real-time biodistribution of nIr-797-labeled shAdAM17cd133+ and shnccd133+ cells in nude mice. 
(A) Fluorescent images of NIR-797-stained shNCCD133+ (up) and shADAM17CD133+ cell migration (down) 1 h and 3 and 10 days after 
intrasplenic vein injection in nude mice after 15- Gy irradiation (2 × 105 cells/mouse). (b) Migration area percentages were analyzed using 
the Maestro Imaging System and Optimas 6.5 software. (c) Fluorescent images show the migration to other organs of NIR-797-stained 
shADAM17CD133+ and shNCCD133+ cells after 15- Gy irradiation following intrasplenic vein injection. (d) NIR signal intensity of mouse 
organs was obtained using the Maestro Imaging System. (e) Mice liver sections stained with H & E (TOP). Representative human albumin 
immunohistochemistry staining of cell migration in mice liver (Bottom). Scale bar, 100 μm.
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MMP-2 and MMP-9 play key roles in tumor invasion and 
metastasis because of their specificity for type IV collagen, 
which is the principal component of the basement membrane 
[41]. In our study, we demonstrated that radiation-induced 
MMP-2 and MMP-9 activities were more predominantly 
increased in Huh7CD133+ cell culture supernatant after 
irradiation. In addition, the secretion of VEGF, which plays 
an essential role in carcinogenesis and metastasis, was 
significantly increased. These results are consistent with a 
previous report that CD133-expressing glioma stem cells 
can promote tumor angiogenesis through hypoxia-induced 
elevated VEGF secretion [42, 43]. Taken together, our 
results showed that irradiation of an HCC cell line enriched 
in the CD133-expressing cell subpopulation led to metastatic 
potential, suggesting that radiotherapy rather than being 
curative may enhance tumor metastasis in HCC. Thus, the 
molecular mechanisms that regulate cell survival or death 
responses to ionizing radiation must be identified to develop 
novel therapies for HCC by targeting key signaling factors.
To investigate the mechanisms underlying the 
maintenance or reinforcement of the migration and 
invasion abilities of liver CSCs following irradiation, 
we performed comparative expression profiling of the 
Huh7CD133+ and Huh7CD133− cell subpopulations. We 
identified 14 metastasis-associated genes responsible 
for cell invasion, migration or angiogenesis in enriched 
Huh7CD133+ cells after irradiation. Among them, ADAM17, 
which is involved in tumorigenesis, was significantly 
increased at both the mRNA and protein levels in 
enriched Huh7CD133+ cells following irradiation. A recent 
study showed that ADAM17 is decreased by hypoxia and 
contributes to hypoxia-induced cisplatin resistance via the 
EGFR/PI3K/Akt pathway in HCC [23]. In this study, we 
demonstrated for the first time that ADAM17 expression 
contributes to the invasion and migration of enriched 
Huh7CD133+ cells after irradiation. To further investigate 
the biological role of ADAM17 in the radiation-associated 
metastatic potential of CSC-enriched HCC cells, we 
suppressed ADAM17 expression using stable shRNA 
in enriched Huh7CD133+ cells after irradiation. Silencing 
of ADAM17 significantly inhibited the migration and 
invasiveness of enriched Huh7CD133+ cells after irradiation. 
Our results are consistent with a previous report that 
ADAM17 is associated with microvascular invasion in 
Figure 8: notch signaling-associated protein expression in shAdAM17cd133+ and shnccd133+ cells following radiation 
exposure. (A) Western blot analysis of NICD protein levels in shADAM17CD133+ and shNCCD133+ cells after 15- Gy irradiation. ß-actin was 
used as a loading control. (b) The band densities were quantified using the TINA imaging analysis software and normalized to β-actin 
expression. The data shown are the means ± SE of three independent experiments. *P < 0.05, shNCCD133+ vs. controls. (c) Western blot 
analysis of HES1 protein levels in shADAM17CD133+ and shNCCD133+ cells after 15- Gy irradiation. ß-actin was used as a loading control. 
(d) The band densities were quantified using the TINA imaging analysis software and normalized to β-actin expression. The data shown are 
the means ± SE of three independent experiments. *P < 0.05, shADAM17CD133+ vs. controls. **P < 0.01, shNCCD133+ vs. controls.
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HCC, which results in disease progression [44]. Next, 
we determined whether these in vitro findings could be 
replicated in vivo. ADAM17-suppressed Huh7CD133+ 
cell migration was significantly inhibited compared 
with that of ADAM17-nonsuppressed Huh7CD133+ cells 
after irradiation based on the NIR fluorescence signals 
detected by in vivo real-time imaging analysis. These 
results suggest that ADAM17 is involved in the radiation-
associated metastatic potential of CSC-enriched HCC 
cells after irradiation and thus may be a potential HCC 
therapeutic target. Moreover, a recent study reported that 
a specific anti-ADAM17 antibody showed anti-tumor 
effects in an ovarian cancer model in vivo [45]. In this 
regard, specific ADAM17 inhibition in combination with 
radiotherapy provides a promising therapeutic approach 
for patients with unrespectable HCC. 
The Notch signaling pathway is involved in 
tumorigenesis and metastasis in various human tumors 
and plays an important role in CSCs [46]. Inhibition of 
Notch induces apoptosis and differentiation in CD133-
expressing stem-like cells enriched from medulloblastoma 
cell lines [47]. Moreover, a recent report demonstrated that 
inhibition of the Notch signaling pathway inhibits HCC cell 
invasion by inactivating MMP-2, MMP-9 and VEGF [25]. 
A more recent study demonstrated that Notch inhibition 
in irradiated glioma stem cells dramatically increased cell 
death within 3 days after radiation, indicating a key role in 
post-radiation survival of glioma stem cells [48]. Another 
study examining the relationship between ADAM17 and 
Notch signaling showed that ADAM17 is a key enzyme 
for activation of the Notch signaling pathway, and that 
inhibition of its activity effectively promotes apoptosis 
and impairs invasion ability in renal cell carcinoma [49]. 
Based on the above results, we investigated the correlation 
between ADAM17 and Notch signaling in enriched 
CD133-expressing liver CSCs after radiation. In our study, 
Notch signaling was significantly reduced in irradiated 
CD133-expressing liver CSCs following stable knockdown 
of the ADAM17 gene. Additionally, HES1 expression 
was significantly reduced in shADAM17CD133+ cells after 
irradiation compared with shNCCD133+ cells. Collectively, 
our results suggest that inhibition of ADAM17 suppresses 
the Notch signaling pathway, resulting in decreased 
MMP-2, MMP-9 and VEGF, leading to inhibition 
of invasion or migration by CD133-expressing liver 
CSCs after irradiation. CD133-expressing CSCs were 
shown to be responsible for cell invasion and migration 
after radiation and their radiation-induced metastatic 
potential could be prevented by suppression of ADAM17 
signaling, suggesting ADAM17 to be a potential target 
for radiotherapy in patients with HCC. In conclusion, 
our findings indicate that after irradiation of HCC cells 
CD133-expressing liver CSCs have significant metastatic 
capabilities, the maintenance of which might be inhibited 
by suppression of ADAM17. Therefore, suppression of 
ADAM17 may reduce the metastatic potential of liver 
CSCs via downregulation of ADAM17.
MAterIAls And MetHods
cell culture and irradiation
Human hepatoma cells (Huh7, Hep3B, SK-hep1 
and PLC/PRF-5) were grown in Dulbecco’s modified 
Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, 
USA) supplemented with 10% fetal bovine serum (FBS, 
Invitrogen), 100 μg/mL penicillin and 0.25 μg/mL 
streptomycin (Invitrogen) and maintained in a humidified 
incubator at 37°C with 5% CO2. Cells were preincubated 
with serum-free DMEM and irradiated at 15- Gy using 
a cesium-137 source delivering 3.1 Gy/min (Gammacell 
3000 Elan irradiator; Best Theratronics, Ottawa, Canada). 
After 15- Gy irradiation, the cells were plated at the same 
density for the in vitro study.
rnA interference
A small interfering RNA (siRNA) method was used 
to knockdown ADAM17. The ADAM17 siRNA sense 
sequences were 5-CAUCAAGUACUGAACGUUUdTdT-3 
and 5-AAACGUUCAGUACUUGAUGdTdT-3. Control 
cells were subjected to mock transfection with scrambled 
siRNA. Transfection was performed using G-fectin 
(Genolution, Korea) following the manufacturer’s protocol.
Flow cytometric analysis
Cells were incubated at 4°C with a phycoerythrin-
conjugated anti-CD133/1 antibody (Miltenyi Biotec, 
Auburn, CA, USA) and analyzed by flow cytometry 
(FACSCalibur; BD Biosciences, San Jose, CA, USA). 
Huh7CD133+ and Huh7CD133− cells were sorted using a 
FACSCalibur cell sorter. Isotype-matched mouse IgG was 
used as a control.
DNA microarray-based gene expression profiling 
in cd133-expressing liver cscs following 
radiation exposure
DNA microarray-based gene expression profiling in 
CD133-expressing liver cancer cells following radiation 
exposure was performed. The mRNA levels of Huh7CD133+ 
and Huh7CD133− cells at 12 and 24 h post-irradiation and 
controls before irradiation were analyzed using the Illumina 
microarray platform (Sentrix Human HT-12v1 BeadChip; 
Illumina, San Diego, CA, USA). Total RNAs were 
extracted, reverse-transcribed, and amplified according 
to the manufacturer’s instructions. The integrity of total 
RNA was analyzed using the 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA). In vitro transcription 
was performed to generate cRNA, which was hybridized 
onto each array. The arrays were scanned using a Bead 
Station (Illumina). Under each condition, we performed 
gene expression profiling of two biological replicates 
obtained from independent cell cultures. The probe 
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intensities were normalized using quantile normalization 
in beadarray 1. The probes were annotated using lumi 1.4, 
an R/Bioconductor package. The full dataset was submitted 
to Gene Expression Omnibus under submission number 
(GSE22247). Differentially expressed genes (DEGs) 
identified by cDNA microarray comparisons were assigned 
to associate the union of DEGs with GO Biological 
Processes (GOBPs) using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID). Several 
GOBPs and KEGG pathways in which the DEGs were 
significantly enriched (p ≤ 0.05) were identified, including 
metastasis-associated processes (motility/cytoskeleton, 
invasion, adhesion and angiogenesis).
AdAM17 knockdown with stable short-hairpin 
sirnA (shrnA) 
To establish a stable Huh7 cell line depleted of 
ADAM17 expression, cells were infected using a short-
hairpin RNA (shRNA)-lentiviral infection system 
(Sigma-Aldrich Co.). We constructed an ADAM17 
shRNA- carrying lentiviral vector, LV-ADAM17. The 
shRNA negative control-lentiviral particle (LV-NC) was 
used as a negative control. To generate stable cells, 1 × 105 
Huh7 cells were plated on 12-well plates, transduced with 
5 MOI lentiviral particles (using 8 μg/mL hexadimethrine 
bromide [(Sigma-Aldrich Co.]), and incubated in DMEM 
containing puromycin (5 µg/mL) at 37°C with 5% CO2. 
Suppression of ADAM17 in stable cells was confirmed by 
RT-PCR and Western blot analyses.
Western blotting
Protein extracts were resolved on 12% and 
10% SDS–PAGE gels, transferred onto nitrocellulose 
membranes (Schleicher & Schuell, Dassel, Germany) 
and blocked in 5% skim milk. The following primary 
antibodies were used according to the manufacturer’s 
instructions: anti-CD133 (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), ADAM17 (ab cam), NICD (Cell 
Signaling Technology, Beverly, MA, USA), MTSS1 (Santa 
Cruz Biotechnology), HES1 (Santa Cruz Biotechnology) 
and β-actin (Sigma-Aldrich Co.). After incubation with 
horseradish peroxidase (HRP)-conjugated anti-mouse or 
anti-rabbit secondary antibodies (Amersham Biosciences, 
Cardiff, UK), specific protein bands were visualized using 
enhanced chemiluminescence (Amersham Biosciences). 
The density of each band was measured using the TINA 
software.
Migration assay
Huh7CD133+ and Huh7CD133− cells were grown 
to 70% confluence in two 60-mm plates prior to 
experimentation for 12 h in 10% FBS after radiation 
treatment. Additionally, cells were washed and detached 
using 2 mM ethylenediaminetetraacetic acid (EDTA) in 
PBS. After complete detachment, cells were resuspended 
in serum-free medium. Migration of Huh7CD133+ and 
Huh7CD133− cells was determined using a 24-well Transwell 
chamber system (Costar 3422, Corning Inc., NY, USA). 
Huh7CD133+ and Huh7CD133+ cells were seeded in the upper 
chamber at 3 × 104 /mL in 0.2 mL serum-free DMEM 
medium. Medium supplemented with 10% fetal bovine 
serum was placed in the bottom well in a volume of 0.8 
ml. After incubation for 12, 24 and 48 h, non-migrating 
cells on the upper side of the filter were removed with a 
cotton swab. The filters were stained with the Three-Step 
Stain Set (Diff-Quik; Sysmex, Kobe, Japan), and the cells 
that migrated to the lower side of the filter were counted 
under a slide scanner (Pannoramic MIDI; 3DHISTECH 
Ltd., Budapest, Hungary) in five randomly selected fields 
(× 200).
Wound healing assay
Cell motility was assessed using a wound-healing 
assay and liver cell imaging. Huh7CD133+ and Huh7CD133− 
cells were grown to a confluent monolayer on Nunclon 
24-well plates (NUNC, MA, USA), serum-starved for 24 h 
and induced with dexamethasone for another 24 h. Then, 
monolayers were wounded using a disposable pipette tip. 
Wound closure was monitored for 48 h using the Cell-IQ 
real-time image capture system (Chip-Man Technologies 
Ltd, Tampere, Finland). To determine whether wound 
closure was the result of cell migration, cells were counted 
followed by Optimas 6.5 software system. 
Gelatin zymography
Huh7CD133+ and Huh7CD133− cell culture media were 
mixed with non-denatured sample buffer (1 M Tris-Cl pH 
6.8, 1% bromophenol blue, 20% SDS). The mixture was 
electrophoresed on a 10% polyacrylamide gel containing 
1 mg/mL gelatin (Sigma-Aldrich Co., St Louis, MO, USA) 
and the gel was rinsed twice in distilled water with 2.5% 
Triton X-100 for 10 min and then incubated in activation 
buffer (50 mM Tris buffer, pH 7.4 containing 5 mM CaCl2 
and 1 μM ZnCl2) at 4°C for 12 h. In gels stained with 
Coomassie brilliant blue R-250, MMP-2 appeared as a 
clear area and the band density was measured using the 
Multigage imaging software.
reverse transcription polymerase chain reaction 
(Pcr)
Total RNA was prepared from shRNA LV-NC and 
ADMA17 shRNA lentiviral particles cells using TRIzol 
reagent (Invitrogen) according to the manufacturer’s 
instructions. cDNA was synthesized from 2- µg total RNA 
and a random primer and Taq polymerase (Promega) were 
used for RT-PCR. The target primer sequences used were 
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as follows: ADAM17 forward: 5′-TTT CAA GGT CGT 
GGT GGT GG-3′, ADAM17 reverse: 5′-TTC CCC TCT 
GCC CAT GTA TC-3′, and β-actin forward: 5′- GGC ACC 
ACA CCT TCT ACA ATG A-3′, β-actin reverse: 5′- CCC 
TCG TAG ATG GGC ACA GT -3′.
enzyme-linked immunosorbent assay (elIsA)
The expression levels of VEGF, were quantified in 
culture media using ELISA. In brief, culture medium was 
dispensed into 96-well microtiter plates (Nalgen Nunc) 
with coating buffer and incubated at 4°C overnight. The 
plates were then rinsed with PBS with 0.05% Tween-20 
(PBST), reacted first with specific antibodies against 
VEGF at 37°C for 1 h and second with the supplied 
horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG (Zymed, San Francisco, CA, USA; diluted 
1:3,000). After washing three times with PBST, the 
plates were developed by incubation for 30 min at room 
temperature with 3,3′, 5,5-tetramethyl benzidine (TMB) 
as the substrate. The reaction was stopped by addition of 
1 M H2SO4 and the absorbance at 450 nm was determined 
using a microplate reader. 
Histologic analysis
Formalin-fixed and paraffin-embedded liver 
specimens were sectioned and stained with hematoxylin 
and eosin (H & E). In addition, immunohistochemistry for 
human albumin was performed using standard protocols. 
After blocking endogenous peroxide activity with 1 wt% 
goat serum in PBS, the sections were incubated with 
primary antibody against human-albumin diluted 1:500 
in antibody diluent at 4°C overnight. After washing, the 
peroxidase EnVision System (HPR rabbit/Mouse Envision 
System TM, DakoCytomation, Denmark) was applied at 
room temperature for 5–10 min. Peroxidase activity was 
detected using 3,3-diaminobenzidine tetrachloride and 
hematoxylin counterstaining.
Animal and tumor cell inoculation 
All animal experiments were performed in 
accordance with institutional guidelines and were approved 
by the Institutional Animal Care and Use Committee of 
The Catholic University of Korea. Four week-old Balb/c 
nude male mice (Central Lab. Animal Inc., Seoul, Korea) 
were housed in the animal facility for least 2 weeks before 
starting the experiments. To investigate the metastatic 
potential of irradiated LCSCs, a total of 106 irradiated 
Huh7CD133+ or Huh7CD133− cells per mouse were injected via 
the tail vein. Mice were assessed daily for tumor formation 
by palpation and survival was monitored daily. The mice 
were euthanized after anesthesia at 10 weeks to determine 
the extent of metastasis. The organs were separated and 
fixed in formaldehyde for H & E staining.
In vivo imaging study
To assess the migration ability of liver CSCs 
in vivo, we performed a cell tracking in vivo real-time 
imaging study using near-infrared fluorescent magnetic 
NEO-LIVE™-Magnoxide 797 nanoparticles (NIR797; 
Biterials, Seoul, Korea) at 0.4 mg/mL. All procedures were 
performed according to the manufacturer’s instructions. 
After irradiation, 2 × 105 cells were marked with NIR-797 
for near-infrared fluorescence imaging and then injected 
into the spleen of the nude mice, and fluorescence 
images were obtained using the Maestro Imaging System 
(Cambridge Research & Instrumentation Inc., MA, USA) 
for data acquisition and analysis. 
statistical analysis
All data are expressed as the means ± standard error 
of the mean from at least three independent experiments. 
Significant differences between among test conditions 
were identified using the Student’s t-test. *P < 0.05, 
**P < 0.01 and ***P < 0.001 was considered significant.
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